Samsung Biologics Co Ltd
KRX:207940
Samsung Biologics Co Ltd
KRX:207940
Price:
955 000
KRW
0.63%
Market Cap:
68T
KRW
Add
Note
Why Create Notes?
Capture your thoughts
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Peter Lynch
Track and Analyze Performance
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Continuous Learning and Adaptation
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
Boost Decision Confidence
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Delete Note
Do you really want to delete this note?
This action cannot be undone.
Alert
Samsung Biologics Co Ltd
955000
+6000 (+0.63%)
| 52 Week Range |
722 000
999 999.9999
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
Delete Alert
This alert will be permanently deleted.
Ask me anything about
Samsung Biologics Co Ltd
Income Statement
Earnings Waterfall
Samsung Biologics Co Ltd
Samsung Biologics Co Ltd
|
Revenue
|
4.4T
KRW
|
|
Cost of Revenue
|
-2.2T
KRW
|
|
Gross Profit
|
2.2T
KRW
|
|
Operating Expenses
|
-809B
KRW
|
|
Operating Income
|
1.3T
KRW
|
|
Other Expenses
|
-291.9B
KRW
|
|
Net Income
|
1.1T
KRW
|
Income Statement
Samsung Biologics Co Ltd
Samsung Biologics Co Ltd
Currency: KRW
| Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||||||||||
| Revenue |
294 622
N/A
|
313 518
+6%
|
329 198
+5%
|
403 868
+23%
|
464 629
+15%
|
488 016
+5%
|
550 229
+13%
|
523 842
-5%
|
535 806
+2%
|
530 135
-1%
|
482 787
-9%
|
566 539
+17%
|
701 592
+24%
|
783 424
+12%
|
1 013 033
+29%
|
1 102 797
+9%
|
1 164 777
+6%
|
1 218 377
+5%
|
1 322 849
+9%
|
1 499 000
+13%
|
1 568 007
+5%
|
1 818 513
+16%
|
2 057 774
+13%
|
2 480 082
+21%
|
3 001 295
+21%
|
3 210 913
+7%
|
3 425 675
+7%
|
3 586 607
+5%
|
3 694 589
+3%
|
3 920 570
+6%
|
4 211 290
+7%
|
4 364 392
+4%
|
|
| Gross Profit | |||||||||||||||||||||||||||||||||
| Cost of Revenue |
(268 088)
|
(267 036)
|
(286 392)
|
(325 904)
|
(332 829)
|
(348 693)
|
(374 291)
|
(351 333)
|
(390 646)
|
(410 600)
|
(394 739)
|
(463 402)
|
(509 584)
|
(503 956)
|
(639 035)
|
(690 902)
|
(748 701)
|
(782 019)
|
(781 146)
|
(829 252)
|
(841 556)
|
(969 680)
|
(1 132 085)
|
(1 282 962)
|
(1 532 847)
|
(1 629 655)
|
(1 705 516)
|
(1 850 808)
|
(1 891 824)
|
(2 040 192)
|
(2 100 223)
|
(2 211 033)
|
|
| Gross Profit |
26 534
N/A
|
46 482
+75%
|
42 806
-8%
|
77 964
+82%
|
131 800
+69%
|
139 324
+6%
|
175 939
+26%
|
172 510
-2%
|
145 160
-16%
|
119 536
-18%
|
88 048
-26%
|
103 137
+17%
|
192 007
+86%
|
279 468
+46%
|
373 999
+34%
|
411 896
+10%
|
416 076
+1%
|
436 358
+5%
|
541 703
+24%
|
669 748
+24%
|
726 451
+8%
|
848 833
+17%
|
925 689
+9%
|
1 197 120
+29%
|
1 468 448
+23%
|
1 581 259
+8%
|
1 720 159
+9%
|
1 735 799
+1%
|
1 802 765
+4%
|
1 880 379
+4%
|
2 111 067
+12%
|
2 153 358
+2%
|
|
| Operating Income | |||||||||||||||||||||||||||||||||
| Operating Expenses |
(56 957)
|
(59 838)
|
(61 453)
|
(63 280)
|
(65 821)
|
(66 754)
|
(71 168)
|
(77 752)
|
(89 481)
|
291 965
|
284 314
|
(106 854)
|
(100 266)
|
(101 758)
|
(99 755)
|
(104 727)
|
(123 290)
|
(131 850)
|
(151 537)
|
(168 705)
|
(189 142)
|
(209 403)
|
(283 345)
|
(397 447)
|
(484 821)
|
(582 307)
|
(637 441)
|
(659 291)
|
(689 085)
|
(737 141)
|
(786 757)
|
(809 002)
|
|
| Selling, General & Administrative |
(50 880)
|
(53 611)
|
(54 738)
|
(55 862)
|
(56 326)
|
(55 321)
|
(57 606)
|
(62 199)
|
(74 866)
|
(84 231)
|
(93 541)
|
(97 198)
|
(91 013)
|
(92 354)
|
(90 508)
|
(94 511)
|
(109 180)
|
(117 875)
|
(137 657)
|
(156 202)
|
(180 348)
|
(200 262)
|
(271 347)
|
(380 390)
|
(417 989)
|
(540 047)
|
(570 693)
|
(570 565)
|
(575 526)
|
(613 122)
|
(655 530)
|
(661 429)
|
|
| Research & Development |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(1 091)
|
(5 106)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(45 884)
|
(16 726)
|
(38 071)
|
(59 186)
|
(81 588)
|
(89 436)
|
(94 672)
|
(103 174)
|
|
| Depreciation & Amortization |
(6 076)
|
(6 226)
|
(6 715)
|
(7 418)
|
(9 495)
|
(11 435)
|
(13 563)
|
(15 543)
|
(14 615)
|
(13 016)
|
(11 368)
|
(9 654)
|
(9 252)
|
(9 403)
|
(9 246)
|
(9 124)
|
(9 003)
|
(8 869)
|
(8 774)
|
(8 489)
|
(8 794)
|
(9 140)
|
(11 998)
|
(17 056)
|
(20 948)
|
(25 533)
|
(28 677)
|
(29 539)
|
(31 971)
|
(34 582)
|
(36 555)
|
(44 399)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(10)
|
0
|
389 212
|
389 223
|
0
|
0
|
0
|
0
|
0
|
0
|
(5 106)
|
(5 106)
|
(4 014)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Operating Income |
(30 423)
N/A
|
(13 354)
+56%
|
(18 645)
-40%
|
14 684
N/A
|
65 979
+349%
|
72 568
+10%
|
104 769
+44%
|
94 758
-10%
|
55 678
-41%
|
411 503
+639%
|
372 365
-10%
|
(3 715)
N/A
|
91 742
N/A
|
177 711
+94%
|
274 244
+54%
|
307 169
+12%
|
292 786
-5%
|
304 508
+4%
|
390 166
+28%
|
501 043
+28%
|
537 309
+7%
|
639 430
+19%
|
642 344
+0%
|
799 674
+24%
|
983 627
+23%
|
998 952
+2%
|
1 082 718
+8%
|
1 076 509
-1%
|
1 113 680
+3%
|
1 143 238
+3%
|
1 324 309
+16%
|
1 344 356
+2%
|
|
| Pre-Tax Income | |||||||||||||||||||||||||||||||||
| Interest Income Expense |
(201 657)
|
(228 243)
|
(183 458)
|
(197 435)
|
(182 728)
|
(200 063)
|
(221 184)
|
(198 879)
|
(134 354)
|
(82 975)
|
(45 810)
|
10 393
|
61 798
|
61 050
|
51 928
|
50 028
|
(25 873)
|
(6 645)
|
15 775
|
30 805
|
32 302
|
49 069
|
21 642
|
(136 593)
|
(33 549)
|
(51 475)
|
(34 744)
|
83 466
|
1 451
|
15 868
|
48 614
|
7 216
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
(11)
|
0
|
389 214
|
0
|
0
|
389 224
|
(359)
|
(1 712)
|
(1 712)
|
(1 712)
|
(1 352)
|
0
|
0
|
0
|
0
|
2
|
64 421
|
65 079
|
65 106
|
65 104
|
772
|
5 185
|
5 159
|
5 159
|
5 072
|
1
|
|
| Gain/Loss on Disposition of Assets |
(1)
|
(4)
|
(4)
|
(5)
|
(45)
|
0
|
(64)
|
0
|
(612)
|
(1 008)
|
(1 098)
|
(1 099)
|
(806)
|
(474)
|
(391)
|
(1 640)
|
(1 841)
|
(1 777)
|
(1 750)
|
(3 483)
|
(7 466)
|
(7 465)
|
(8 225)
|
(6 906)
|
(2 588)
|
(2 704)
|
(1 957)
|
(1 064)
|
(3 866)
|
(3 765)
|
(4 168)
|
(3 289)
|
|
| Total Other Income |
1 180
|
1 106
|
979
|
987
|
798
|
900
|
931
|
873
|
(6 950)
|
(6 830)
|
(6 331)
|
(5 731)
|
3 060
|
3 279
|
3 168
|
2 872
|
2 272
|
1 908
|
1 070
|
413
|
(863)
|
(1 000)
|
(699)
|
(589)
|
(3 573)
|
(2 728)
|
(2 792)
|
(2 230)
|
3 563
|
2 917
|
3 235
|
3 465
|
|
| Pre-Tax Income |
(230 901)
N/A
|
(240 495)
-4%
|
(201 129)
+16%
|
(181 768)
+10%
|
(115 995)
+36%
|
(126 595)
-9%
|
(115 560)
+9%
|
(103 248)
+11%
|
302 976
N/A
|
320 688
+6%
|
319 126
0%
|
389 070
+22%
|
155 435
-60%
|
239 854
+54%
|
327 235
+36%
|
356 716
+9%
|
265 992
-25%
|
297 995
+12%
|
405 262
+36%
|
528 778
+30%
|
561 283
+6%
|
680 037
+21%
|
719 484
+6%
|
720 665
+0%
|
1 009 025
+40%
|
1 007 150
0%
|
1 043 997
+4%
|
1 161 866
+11%
|
1 119 987
-4%
|
1 163 416
+4%
|
1 377 062
+18%
|
1 351 748
-2%
|
|
| Net Income | |||||||||||||||||||||||||||||||||
| Tax Provision |
54 078
|
56 301
|
44 870
|
37 915
|
19 023
|
16 036
|
7 569
|
(27)
|
(78 867)
|
(84 598)
|
(76 917)
|
(75 735)
|
47 469
|
38 152
|
16 202
|
(1 340)
|
(25 017)
|
(32 696)
|
(70 459)
|
(118 284)
|
(167 693)
|
(200 481)
|
(209 409)
|
(213 200)
|
(210 968)
|
(214 281)
|
(218 283)
|
(224 949)
|
(262 296)
|
(268 118)
|
(348 658)
|
(299 243)
|
|
| Income from Continuing Operations |
(176 823)
|
(184 194)
|
(156 259)
|
(143 853)
|
(96 972)
|
(110 558)
|
(107 989)
|
(103 273)
|
224 109
|
236 091
|
242 210
|
313 337
|
202 904
|
278 008
|
343 438
|
355 375
|
240 975
|
265 298
|
334 801
|
410 494
|
393 589
|
479 557
|
510 074
|
507 465
|
798 056
|
792 869
|
825 714
|
936 917
|
857 691
|
895 298
|
1 028 404
|
1 052 506
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Net Income (Common) |
(176 823)
N/A
|
(184 194)
-4%
|
(156 259)
+15%
|
(143 853)
+8%
|
(96 972)
+33%
|
(110 558)
-14%
|
(107 989)
+2%
|
(103 273)
+4%
|
224 109
N/A
|
236 091
+5%
|
242 210
+3%
|
313 337
+29%
|
202 904
-35%
|
278 008
+37%
|
343 438
+24%
|
355 375
+3%
|
240 975
-32%
|
265 298
+10%
|
334 801
+26%
|
410 494
+23%
|
393 589
-4%
|
479 557
+22%
|
510 074
+6%
|
507 465
-1%
|
798 056
+57%
|
792 869
-1%
|
825 714
+4%
|
936 917
+13%
|
857 691
-8%
|
895 298
+4%
|
1 028 404
+15%
|
1 052 506
+2%
|
|
| EPS (Diluted) |
-3 102.15
N/A
|
-2 790.81
+10%
|
-2 367.56
+15%
|
-2 179.59
+8%
|
-1 469.27
+33%
|
-1 675.12
-14%
|
-1 636.19
+2%
|
-1 564.74
+4%
|
3 395.59
N/A
|
3 577.13
+5%
|
3 669.84
+3%
|
4 747.53
+29%
|
3 074.3
-35%
|
4 212.24
+37%
|
5 203.6
+24%
|
5 384.46
+3%
|
3 651.13
-32%
|
4 019.66
+10%
|
5 000.89
+24%
|
6 131.5
+23%
|
5 879.01
-4%
|
7 163.09
+22%
|
7 219.15
+1%
|
7 129.92
-1%
|
11 431.89
+60%
|
11 139.86
-3%
|
11 601.34
+4%
|
13 163.75
+13%
|
12 050.63
-8%
|
12 579
+4%
|
14 449.16
+15%
|
14 787.79
+2%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
